H. Ohta et al., MEASUREMENT OF SIALYLATED STAGE-SPECIFIC EMBRYONIC ANTIGEN-1 IN PURE PANCREATIC-JUICE FOR THE DIAGNOSIS OF PANCREATIC-CANCER, International journal of pancreatology, 15(1), 1994, pp. 35-41
The diagnostic significance of measuring sialylated stage-specific emb
ryonic antigen-1 (SLX) in pure pancreatic juice was evaluated in 20 pa
tients with pancreatic cancer, 43 with chronic pancreatitis, 13 with c
holecystolithiasis, and 15 control individuals. Four fractions of pure
pancreatic juice were collected sequentially from the pancreatic duct
by endoscopic cannulation. The SLX levels in all four fractions of pu
re pancreatic juice were significantly higher in patients with pancrea
tic cancer than in controls. On the other hand, patients with chronic
pancreatitis or cholecystolithiasis did not have SLX levels that signi
ficantly differed from those of controls in any fraction. When the cut
-off value was set as the mean concentration + 2 times the standard de
viation of the control values, the positive rates of SLX in the first
fraction (washout phase) and the third fraction (secretory phase) of p
ure pancreatic juice from pancreatic cancer were 55% (11/20) and 40% (
8/20), respectively. Although the false positive rates in the first fr
action were high in chronic pancreatitis (30%) and cholecystolithiasis
(31%), such high SLX levels in the third fraction were found only in
one (2%) patient with chronic pancreatitis and in one (8%) with cholec
ystolithiasis. The specificities of the test for pancreatic cancer in
the first fraction and the third fraction were 70% (39/56) and 96% (54
/56), respectively. These results indicate that the measurement of SLX
in the third fraction of pure pancreatic juice is useful as a specifi
c marker for pancreatic cancer.